SCHEMBL269331

SCHEMBL269331

O=C(O)c1ccccc1-c1ccccc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
ACMSD Q8TDX5 1/20 0.56
ALB P02768 1/20 0.55
ALDH1A1 P00352 4/20 0.54
ALOX15 P16050 2/20 0.54
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX12 P18054 1/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
MYC P01106 1/20 0.50
GAA P10253 1/20 0.50
GPR35 Q9HC97 2/20 0.49
FOLH1 Q04609 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
HNF4A P41235 1/20 0.47
DHODH Q02127 1/20 0.47
KDM4E B2RXH2 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL36145 0.86 ALDH1A1 (0.72) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
SCHEMBL30028907 0.86 ALDH1A1 (0.72) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
SCHEMBL2342315 0.86 NPC1 (0.55) NPC1RAB9AACMSDALBALDH1A1
SCHEMBL6055008 0.84 ALB (0.69) NPC1RAB9AACMSDALBALDH1A1
Hydrochloric Acid SCHEMBL10888462 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
SCHEMBL30620175 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
SCHEMBL28408894 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
SCHEMBL2830888 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
Hydrochloric Acid SCHEMBL7579852 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12
Hydrochloric Acid SCHEMBL1681943 0.84 ALDH1A1 (0.68) ALDH1A1ALOX15CYP3A4CYP2C9ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240389450-A1 LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE Sharp Display Technology Corporation (JP) 2024-11-21 US claimed
CN-117981493-A Light-emitting element, method for manufacturing light-emitting element, display device, and method for manufacturing display device 夏普显示科技株式会社 2024-05-03 CN claimed
WO-2023079616-A1 LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE シャープディスプレイテクノロジー株式会社 2023-05-11 WO claimed
EP-0057141-B1 ESTERS OF HALOGENE-BIPHENYLCARBOXYLATES, METHOD OF PREPARATION AND THEIR APPLICATION AS MEDICINES PIERRE FABRE S.A. (FR) 1984-04-04 EP claimed
US-20240389450-A1 LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE Sharp Display Technology Corporation (JP) 2024-11-21 US disclosed
CN-117981493-A Light-emitting element, method for manufacturing light-emitting element, display device, and method for manufacturing display device 夏普显示科技株式会社 2024-05-03 CN disclosed
WO-2023079616-A1 LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE シャープディスプレイテクノロジー株式会社 2023-05-11 WO disclosed
CN-107835680-A The novel beta hydroxysteroid dehydrogenase of 1 type of selectivity 11 帝斯曼知识产权资产管理有限公司 2018-03-23 CN disclosed
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-8133901-B2 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2012-03-13 US disclosed
US-20060199837-A1 SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE AVENTIS PHARMA S.A. (FR) 2006-09-07 US disclosed
CN-1626534-A Steroid receptor modulator compounds and methods LIGAND PHARM INC (US) 2005-06-15 CN disclosed
US-20050096345-A1 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use AVENTIS PHARMA S.A. (FR) 2005-05-05 US disclosed
CN-1172917-C Steroid receptor modulator compounds and methods ��λ��ҩ��ɷ����޹�˾ 2004-10-27 CN disclosed
CN-1175247-A Steroid receptor modulator compounds and methods LIGAND PHARM INC (US) 1998-03-04 CN disclosed
US-5312564-A Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same CHISSO CORPORATION (JP) 1994-05-17 US disclosed
US-4780242-A BIPHENYL ESTERS CHISSO CORPORATION (JP) 1988-10-25 US disclosed
EP-0197677-A2 Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same Chisso Corporation (JP) 1986-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199837-A1 SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE BRD4, TP53, HCCS NPC1 4105/4885RAB9A 1322/4885ACMSD 4794/4885
US-20130158050-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C NPC1 580/4885RAB9A 358/4885ACMSD 744/4885
US-20050096345-A1 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use BRD4, TP53, HCCS NPC1 3940/4885RAB9A 1433/4885ACMSD 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.